Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.
about
Pretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillationThe Different Therapeutic Choices with ARBs. Which One to Give? When? Why?Losartan prevents stretch-induced electrical remodeling in cultured atrial neonatal myocytesComparing angiotensin II receptor blockers on benefits beyond blood pressureAtrial fibrillation.The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials.Atrial Fibrillation Complicating Congestive Heart Failure: Electrophysiological Aspects And Its Deleterious Effect On Cardiac Resynchronization TherapyImpaired kidney function and atrial fibrillation in elderly subjects.Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillationAngiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis.Serological predictors for the recurrence of atrial fibrillation after electrical cardioversion.Recent advances in pharmacotherapy of atrial fibrillationDo we need more than just powerful blood pressure reductions? New paradigms in end-organ protectionThe past, present and future of renin-angiotensin aldosterone system inhibitionRemodeling of ion channel expression in patients with chronic atrial fibrillation and mitral valvular heart disease.Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'.Effect of renal sympathetic denervation on atrial substrate remodeling in ambulatory canines with prolonged atrial pacingAntiarrhythmic drugs: new agents and evolving concepts.Angiotensin II and angiotensin II receptor blocker modulate the arrhythmogenic activity of pulmonary veinsHeart failure complicated by atrial fibrillation: mechanistic, prognostic, and therapeutic implications.Recent advances in drug therapy for atrial fibrillation.Primary stroke prevention and hypertension treatment: which is the first-line strategy?Atrial fibrillation and heart failure parallels: lessons for atrial fibrillation prevention.Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics.C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion.Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013.Antiarrhythmic drugs: past, present and future.The renin-angiotensin-aldosterone system in atrial fibrillation: a new therapeutic target?Atrial fibrillation in heart failure: prognostic significance and management.Antiarrhythmic drugs in atrial fibrillation: an overview of new agents, their mechanisms of action and potential clinical utility.Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation.Management of atrial fibrillation in patients with congestive heart failure.Beta-Adrenergic blockers as antiarrhythmic and antifibrillatory compounds: an overview.Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence.Rate versus rhythm control in the management of patients with atrial fibrillation.Targeting the renin-angiotensin-aldosterone-system in atrial fibrillation: a shift from electrical to structural therapy?Drug therapy for atrial fibrillation: where do we go from here?Is atrial fibrillation an inflammatory disorder?Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence.Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation--indications and contraindications.
P2860
Q24801156-A9154DE4-DD27-4FD6-8F4D-E97190CAF57EQ26768696-4FD8DDBF-418F-4106-9A40-888956079C0FQ28573802-16650663-7B1C-4D36-B413-D0ABE47FA66DQ30360678-B606B9DE-F2EE-46DD-8225-038CD85B8FC4Q30832817-22E719F2-F461-4A1A-BBFC-BD47F464DAD0Q33208464-C62DC4B4-144F-464C-9905-B05A8DF8385FQ33585671-6CFC6D3F-8EF5-42C3-9B4B-DE78A2C97F0CQ33635948-CC7BF6E2-795D-480E-9F94-96DB94C77724Q33680031-7F891A87-2966-4B30-BF19-1FCBF2937F4EQ33798432-79DCB9C2-819B-4FE5-9F98-33A5CC1D8493Q33809189-DFEAEA8E-77F4-431D-AED6-65B25FEA524AQ33874035-7C61F063-81F7-4547-9306-89DCF085C0A3Q34068728-A9BA41E9-4899-4C85-BD79-7D3591E471FAQ34094354-E6400CFA-E8BD-4D73-8EA4-DB3868C37946Q34385013-7673CE71-C276-4FD4-8DF8-1BC842297602Q34609020-83C084D6-8569-4C80-99F3-311CFABE7B8AQ34749676-F5B31BDB-FFE9-47F0-BD5D-891A52B3BA4AQ35073365-9C64ADC8-4C1B-4274-8218-2BE74FBCD002Q35098594-FEED1102-9D56-4A26-B04E-B6ED59BE9CA0Q35155253-6ABA6018-5A12-4CE4-9284-C5E9D0F45B5DQ35209693-C4CEE0CE-9F8E-4CBD-8AA6-BAB5D3A5005BQ35513559-EBA1EA50-3720-4E82-B845-D9F4076981F6Q35563922-E3F57732-7740-411B-8836-3076AF9651EAQ35582807-06EFF4C3-8AED-43B2-B888-E7BB7FA76F6DQ35584790-4F35C25F-FEA5-4240-883A-5E54C57BB792Q35585789-5387CA90-1F00-4093-9FC4-7CA7DF24DCCBQ35608800-B4DF7049-FF5E-4F26-97E5-24775A82D7E6Q35671248-9CC3FCC1-3C89-4F0D-B856-FC391D662AF3Q35684055-ED57317F-16F2-4133-8B4F-11F49EBA1E33Q35814463-17D8BD5F-40E3-4C90-B94C-6DF333968D3AQ35941124-5F8EC322-65AC-44D8-9E36-6FC9736E72C0Q36077788-4181C626-CB77-41B5-A51F-B29D50BC10DAQ36167681-C44A88C7-1DB4-4B7F-8BE9-C5525010A440Q36210252-2C1BEEDC-068D-449F-A7C5-301DB13F4167Q36269171-410FE594-369B-400D-BD09-BB42A8F0AEB1Q36283707-373B3A62-4C93-4669-AFEA-8FCBA7441062Q36303805-BEF45732-64D8-4E49-B5AA-03925B8A0423Q36309624-9B77F44C-8205-41A3-9175-D26701201CF5Q36324110-747CD0E8-1118-4794-8A30-EB9F50E15359Q36433583-C7261E6C-1E1B-4D6E-A9FE-99C019E00426
P2860
Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Use of irbesartan to maintain ...... spective and randomized study.
@en
Use of irbesartan to maintain ...... spective and randomized study.
@nl
type
label
Use of irbesartan to maintain ...... spective and randomized study.
@en
Use of irbesartan to maintain ...... spective and randomized study.
@nl
prefLabel
Use of irbesartan to maintain ...... spective and randomized study.
@en
Use of irbesartan to maintain ...... spective and randomized study.
@nl
P2093
P1433
P1476
Use of irbesartan to maintain ...... ospective and randomized study
@en
P2093
Antonio H Madrid
Aníbal Rodriguez
Concepción Moro
Gonzalo Peña
Irene Marín
Jose M G Rebollo
José M Cano
Lucas Cano
Manuel G Bueno
Pedro Cabeza
P304
P356
10.1161/01.CIR.0000022665.18619.83
P407
P577
2002-07-01T00:00:00Z